Lead Investigator: Qingyun Li, Genecast Biotechnology Co., Ltd
Title of Proposal Research: An exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer
Vivli Data Request: 7804
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
The incidence of non-small cell lung cancer (NSCLC) in China in men is about 50 cases per 100,000 people, and in women it is closer to 30 per 100,000.
A fusion gene is when two genes are joined at the beginning and end to form a new gene. As technology has developed, fusion genes have been identified more frequently in lung cancer, with the ALK receptor tyrosine kinase (ALK) / ret proto-oncogene (RET) / ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) rearrangements are the most common genes. A patient who has a fusion with another type of variations is known as a co-mutant. Patients with ALK fusions are usually treated with ALK-specific tyrosine kinase inhibitors (TKIs), but patients with co-mutant are less effective with ALK-TKIs. The aim of this article is to explore the reasons for the differences in efficacy in patients with and without co-mutations and to provide an immune microenvironmental perspective. In the long term, the prognosis of patients and the efficacy of treatment can be predicted by whether they have a co-mutation or not, and provide more precise treatment options for these co-mutant patients.
The present study is a retrospective analysis of the differences between the two groups of cases with and without the co-mutation to provide an insight into the prognosis of the patients. And it will study the differences in their immune microenvironment to find out if there are statistically significant differences.
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02366143
Sponsor ID: GO29436
Update: This data request was withdrawn on 6-Jul-2023 by the researcher.